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I. 
BINDING  OF  SOLUBLE  IMMUNE  COMPLEXES  TO 
HUMAN  LYMPHOBLASTOID  CELLS 
Characterization  of Receptors  for IgG Fc and Complement and 
Description of the Binding Mechanism* 
BY ARGYRIOS  N.  THEOFILOPOULOS,$  FRANK  J.  DIXON,  AND VIKTOR  A.  BOKISCH§ 
(From the Department of Experimental Pathology, Scripps  Clinic and Research Foundation, 
La Jolla, California 92037) 
Human bone marrow-derived (B type) lymphocytes have receptors for IgG Fc (1) 
and the C3b and C3d fragments of C3 (2, 3). The contribution of each receptor to 
the  binding  of soluble  immune  complexes  which  have  interacted  with  comple- 
ment has not yet been thoroughly investigated.  The present studies were under- 
taken to characterize  the binding of IgG Fc and complement by various lympho- 
blastoid cell lines in the hope that these cells might serve as in vitro detectors of 
immune complexes.  As a  model for immune complexes we employed aggregated 
human gamma globulin  (AHG) 1 before and after interaction with human serum 
as source of complement, and observed its binding via receptors for IgG Fc, C3b, 
and  C3d  on  the  lymphoblastoid  cell  surface.  Human  lymphoblastoid  cell  lines 
with B-cell  characteristics  were chosen for study since it was felt that they would 
be a  more convenient  and homogeneous indicator system than any other source 
of  lymphoid  cells.  Nine  such  lymphoblastoid  cell  lines  were  characterized  for 
membrane-bound Ig (MBIg)  and receptors for IgG Fc and complement. The Raji 
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Abbreviations  used in this paper: AHG, aggregated human gamma globulin; BSA, bovine serum 
albumin;  C,  complement;  C3bina,  C3b  inactivator;  DEAL,  diethylmethyl-cellulose;  EA,  anti- 
body-sensitized  sheep  erythrocytes;  EAC',  complement  coated  sensitized  sheep  erythrocytes; 
EAC1423b  hu, EA coated with isolated human C1,  C4, C2, C3; EAC1423d  hu, EA coated with human 
C1, C4,  C2, C3 and then rendered immune adherence negative; EACI-3 mo, EA coated with C1-C3 
from mouse serum deficient in C5; EACI-5 rab, EA coated with C1-C5 from rabbit serum deficient in 
C6; FITC, fluorescein isothiocyanate; GVB, Veronal-buffered (5 mM) saline containing 1.0% gelatin, 
1.5  ×  10  '  M  CaCI~,  5  ×  10 .4  M  MgC12;  HSA,  human serum  albumin; MBIg,  membrane-bound 
immunoglobulin;  MEM,  minimum essential  medium;  NHS,  normal  human  serum;  PBS,  phos- 
phate-buffered saline; RBC, red blood cell. 
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cell line lacking  MBIg  but  having  receptors  fbr IgG Fc,  C3b, and  C3d was selected 
for  assaying  the  contribution  of  these  receptors  to  the  binding  of  AHG.  This 
study  revealed  that  soluble  AHG  containing  complement  binds  to  the cells only 
via the  receptors  fbr C3b  and  C3d. 
Materials  and Methods 
Lymphoblastoid  Cell Lines.  Raji and Daudi cell lines were derived from patients with Burkitt's 
lymphoma (4, 5). 8866 cells were derived from the peripheral blood of a patient with acute myelocytic 
leukemia (6) and Wil2WT cells were cultured from the spleen of a patient with hereditary spherocytic 
anemia (7). The SCRF5001,  SCRF5004,  and SCRF5005  human cell lines were provided by Dr.  B. 
Croker, Scripps Clinic. The SCRF5001 and SCRF5004 lines were derived from peripheral blood of two 
patients with  systemic  lupus erythematosus; the  SCRF5005  line was  derived from  the  peripheral 
blood of a patient with SjSgren's syndrome. The Sommer 8432 and Sommer 8402 cell lines were pro- 
vided by Dr.  G. E. Moore, Denver General Hospital, Denver, Colo. and were cultured from the pe- 
ripheral blood of a  patient with acute lymphocytic leukemia. Suspension cultures of these cell lines 
were propagated in Eagle's minimum essential medium (MEM; Autopow, Flow Laboratories, Inc., 
Rockville, Md.) supplemented with glutamine, nonessential amino acids, pyruvate, 10% fetal bovine 
serum,  penicillin, streptomycin,  and fungizone, as described by Lerner et al. (8).  Cell viability was 
determined by trypan blue exclusion. 
C3 and C3b.  C3 was prepared from human serum according to the method described by Nilsson 
and M/iller-Eberhard (9). The C3b fragment was prepared by enzymatic cleavage of C3 with trypsin 
(10)  and was isolated by column chromatography and pevikon electrophoresis. 
Aggregated  Human  Gamma  Globulin  (AHG).  Human  IgG  was  prepared  by fractionation of 
human  gamma  globulin  FI!  (Miles  Laboratories,  Inc.,  Kankakee,  Ill.)  on  a  DEAE-52  cellulose 
column. IgG (10 mg/ml) was conjugated with fluorescein isothiocyanate (FITC) as in (11)  and was 
aggregated subsequently by heating at 63°C for 20 min. Soluble fluorescein-conjugated aggregated 
human gamma globulin (FITC AHG), prepared after centrifugation of the aggregates at 1,500 g for 30 
min., was used in a concentration of 2 mg/ml of phosphate-buffered saline (PBS), pH 8.0. 
Radioiodination.  AHG was iodinated with 125I according to the method of McConahey and Dixon 
(12). Human IgG (2 mg/ml) was first aggregated by heating (63°C, 30 min), freed of large insoluble 
aggregates by centrifugation at 1,500 g for 30 min and then iodinated.  [125I]AHG was dialyzed against 
PBS for 24 h and then centrifuged at 2,000 g for 30 min in order to remove any insoluble aggregates. 
The specific activity of the preparation used was 3  ×  105 cpm/tLg protein. 
Antisera.  Antihuman C3 serum was prepared by immunizing rabbits with isolated C3 (10). When 
tested by double diffusion in agar, the antihuman C3 serum (2 mg/ml) used in this study reacted with 
C3 and the fragments C3b, C3c, and C3d. This serum gave a single precipitin line when tested against 
normal human serum (NHS) or isolated C3 on Ouchterlony analysis and immunoelectrophoresis. The 
antimouse C3 serum (1 mg/ml) was prepared in rabbits as described (13). The goat antirabbit C3 (0.8 
mg/ml, lot 57411)  and goat antiguinea pig C3 (1.2 mg/ml, lot 5632)  sera were purchased from Cappel 
Laboratories, Inc.  (Dowington,  Pa.)  and gave only one line when tested against the corresponding 
serum by Ouchterlony analysis and immunoelectrophoresis. The rabbit antihuman immunoglobulin 
serum (IgG +  IgA +  IgM; 1.5 mg/ml, lot 6684) was purchased from Cappel Laboratories. The rabbit 
antihuman IgG serum was prepared by immunizing rabbits with human IgG. The IgG fraction of all 
antisera listed above was used. 
Immunofluorescent  Staining.  Antisera were conjugated with FITC according to the method of 
Clark and Shepard (11). In a typical experiment, 5 ×  108 cells in 50t~l of MEM without Ca ++ and with 
100 ttg of isolated human C3 or C3b or 50 ttl of human, mouse, rabbit or guinea pig serum (freshly 
obtained or previously stored at  -70°C)  were incubated with gentle agitation at 37°C  for 30 min. 
Subsequently, cells were washed three times with MEM and incubated with gentle agitation for 30 
min at 4°C with 25 ttl of the corresponding FITC antiserum to C3. The specificity of the staining was 
demonstrated  by  repeatedly  absorbing  FITC  antihuman  C3,  FITC  antirabbit  C3  and  FITC 
antimouse C3 serum with EAC1423b h  ....  (EAC1423bhu), EAC1-5 rabbit (EAC1-5 rab), or EAC1-3 
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with human, rabbit, or mouse C3. To demonstrate membrane-bound Ig (MBIg) on human lymphoid 
cells, a direct fluorescence technique was employed in which 50 #l of lymphoid cell suspension (5  × 
108 cells) were incubated (4°C,  30 min) with 25 #l of FITC  antihuman Ig serum. To demonstrate 
binding of AHG to human lymphoblastoid cells, both direct and indirect techniques were employed. 
In the direct method, 5  ×  108 cells in 50 t~l MEM were incubated (37°C, 30 min) with 25 #l of FITC 
AHG. In the indirect method, cells were first incubated (37°C, 30 min) with FITC AHG, washed three 
times with MEM, and then reacted (4°C, 30 min), so as to cross-link FITC AHG molecules possibly 
bound to cells, with nonconjugated rabbit antihuman IgG serum. Before use the FITC  AHG was 
centrifuged at  1,500 g for 20  rain in order to remove large aggregates. In the final step, cells were 
washed three times with MEM and resuspended in 10 ttl of 10% bovine serum albumin (BSA) in PBS. 
Cell  smears  were  air  dried,  fixed  in  95%  cold  ethanol,  and  mounted  under  glycerogel.  Wet 
preparations were made by sealing a drop of the cell suspension with paramount under a cover slip. 
Smears were observed by using a  Zeiss interference filter system utilizing transmitted light from a 
HBO 200 watt mercury light source. Since all cells in a given preparation stained to the same degree, 
we could semiquantitatively classify the  intensity of stain  from negative to  3+  for both surface 
immunoglobulin and aggregate binding. 
Erythrocyte-Antibody  Complement  Complexes.  EAC1423b  hu  cells were  prepared  from  sheep 
erythrocytes  (E)  (1  ×  109  cells/ml)  sensitized  with  rabbit  antierythrocyte  antibody  (A),  and 
incubated with purified human  complement (C)  components as  previously described (14).  EAC- 
1423b hu were stored at a concentration of 1 ×  109 cells/ml GVB (Veronal-buffered saline containing 
1.0% gelatin,  1.5  ×  10  '  M  CaCl2  and 5  x  10 _4 M  MgC12). EAC1-3 mo and EAC1-5 rab cells were 
prepared by incubating (37°C, 30 rain) sensitized sheep erythrocytes (5  ×  l0 s cells) in 1 ml mouse 
serum diluted 1 : 5 with GVB or rabbit serum diluted 1 : 2 with GVB. Cells were washed three times 
and stored in  GVB  (1  ×  109  cells/ml). The mouse serum was obtained from B10D2  old line mice 
(Jackson Laboratories, Bar Harbor, Maine) genetically deficient in C5  (15).  The rabbit serum was 
obtained from C6-deficient rabbits (16). Each batch of EAC' cells could be used over a  period of 7 
days. 
EAC1423d  hu  cells were obtained by  incubating (37°C,  120  min)  5  ×  107  EAC  1423b hu  with a 
sufficient amount of C3b inactivator  ~ (C3bina)  or heat-inactivated (56°C,  30 rain) human serum to 
make them immune adherence negative.  C3bina  cleaves C3b  into C3c and  C3d and treatment of 
EAC1423b  hu with C3bina results in release of C3c and retention of C3d on the red cell surf'ace  (17). 
EAC1423d  hu are immune adherence negative. 
Rosette Formation  of Cells Bearing Receptors for Complement with EAC'. 2  x  108 lymphoblas- 
told cells were incubated in small plastic Eppendorf conical tubes (Brinkman Instrument Co.,  Los 
Angeles, Calif.)  with 5  ×  107  EAC' in a  total vol of 200 #l of MEM  without Ca ++, at 37°C for 30 
min, during which time the mixture was shaken twice by hand. Thereafter, the cells were suspended 
in 1 ml MEM and placed on ice for 5 min. Rosetted (four or more bound erythrocytes) and unrosetted 
lymphocytes were counted in a hematocytometer, using a  Zeiss phase-contrast microscope, and the 
percent of rosette-forming cells was calculated. 
Rosette  Formation  with  Sheep  Erythrocytes.  The  method  of  Jondal  et  al.  (18),  with  the 
modification of Bentwich et al.  (19) was employed. In preliminary experiments it was found that 
approximately 60% of human peripheral lymphocytes (average of 15 experiments) formed rosettes. 
None of the human  lymphoblastoid cell lines studied here formed spontaneous rosettes with sheep 
erythrocytes. 
Immune Adherence.  Immune adherence experiments were performed in microtiter plates (Cooke 
Engineering Co., Alexandria, Va.). In a typical experiment, each well was filled with 25 ~1 of Veronal 
buffer, pH 7.5, T/20.1, containing 0.1% human serum albumin (HSA). 25 ~l of 1 ×  10 ~ EAC/ml were 
placed in the first well and dilutions were made with a 25 ul microtiter loop. After addition of 25 ul of 
human O group red cell suspension containing 2 x  108 red cells per ml to all wells, the plates were 
agitated for 5 rain and then incubated at 37°C for 30 min, after which time the sedimentation pattern 
was evaluated. 
Trypsin  Treatment.  5 ×  106 cells were incubated with 0.01% trypsin in MEM (wt/vol) for 15 min 
at 37°C and then washed twice with 0.1% soy bean trypsin inhibitor in MEM. 
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Results 
Membrane-Bound Ig and Receptors for IgG Fc.  Six out of the nine human 
cell lines were found to carry MBIg, as shown with a rabbit antihuman Ig serum 
(Table I).  Daudi  cells gave the most intense staining; 8866 and Wil 2WT cells 
were  weakly  positive.  An  intermediate  intensity  of  staining  was  seen  with 
SCRF5001,  SCRF5004,  and  SCRF5O05 cells. In contrast to the other cell lines, 
Raji,  Sommer  8432  and  Sommer  8402  cells  were  negative  for  MBIg  by 
immunofluorescence. The presence of receptors for IgG Fc on the different cell 
lines was shown by a direct method in which FITC AHG was used and a two-step 
indirect method in which cells preincubated with FITC AHG were reacted with 
nonconjugated  antihuman  IgG.  As  judged  by  intensity  of  fluorescence,  the 
TABLE I 
Presence  of MBIg and Receptors/or IgG Fc on Human Lymphoblastoid Cells 
Cell type 
MB Ig  Receptors for IgG Fc* 
Fluorescence  Intensity of  Fluorescence  Intensity of 
positive cells  fluorescence  positive cells  fluorescence 
%  % 
Daudi  100  3 +  100  2 + 
8866  100  1 +  0  Neg 
WiI2WT  100  1 +  0  Neg 
SCRF5001  100  2 +  100  1 + 
S CRF5004  100  2 +  100  1 + 
SCRF5005  100  2 +  100  1 + 
Raji  0  Neg  100  1+ 
Sommer 8432  0  Neg  100  1+ 
Sommer 8402  0  Neg  0  Neg 
* Results given were obtained by the indirect method. 
indirect method was more sensitive in detecting membrane bound AHG than the 
direct one. 8866,  Wil2WT, and Sommer 8402 cells did not bind AHG with either 
method.  Raji  and  Daudi  cells  were  positive  by  both  methods,  whereas  the 
SCRF5001, SCRF5004, SCRF5005, and Sommer 8432 cells were positive only by 
the more sensitive indirect method. The strongest intensity of staining was found 
with Daudi cells, which indicated the presence of a large number of receptors for 
Fc on this  cell type. When  the  presence of MBIg and  receptors for IgGFc are 
compared, as shown in Table I, four categories of cell lines can be distinguished: 
(a) Daudi,  SCRF5001,  SCRF5004,  and  SCRF5005 cells which have both MBIg 
and receptors for IgG Fc, (b) 8866 and Wil2WT cells which have MBIg but lack 
receptors for IgG Fc,  (c) Raji and Sommer 8432  cells which have no MBIg but 
which have receptors for IgG Fc, and (d) Sommer a402 cells which have neither 
MBIg nor receptors for IgG Fc. 
Receptors for Erythrocyte-Bound  C3b and C3d.  Receptors for red cell-bound 
C3b and C3d have been found on human B-type lymphocytes (3, 20) and on Raji 
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of these  receptors  by  rosette  formation  with  EAC1423b hu,  EAC  1423d hu,  and 
EAC1-3  mo.  EAC1-3  mo  prepared  with  C5-deficient  mouse  serum  have  been 
shown  to carry  C3d  (3).  These cells  gave no  immune  adherence reaction with 
human group O  erythrocytes. Tabie II shows the percent of cells of each cell line 
forming rosettes  with  sensitized cells carrying C3b  or C3d.  Three categories of 
cells  can  be  distinguished:  (a)  Raji,  SCRF5001,  SCRF5004,  SCRF5005,  and 
Sommer 8432  cells which  have receptors for red  cell-bound  C3b  and  C3d,  (b) 
Daudi and Sommer 8402 cells which have receptors only for red cell-bound C3d, 
and  (c) 8866 and Wil2WT cells which lack both receptors. 
Distinction Between the Receptors for  C3-C3b and  C3d.  It has been shown 
that the receptor for C3 and C3b is the same, because C3, C3b, or NHS inhibited 
Raji-EAC1423b hu rosette formation (14). Since certain cells formed rosettes with 
both EAC1423b and EAC1423d, the possibility of the receptors for C3b and C3d 
TABLE II 
Rosette Formation  Between Human LymphobIastoid 
Cells-EAC1423b  h~, EAC1423d h" and EAC1-3 mo 
Cell type 
Percentage of lymphoid cells forming 
rosettes with: 
EAC1423b hu  EAC1423d ~u  EAC1-3 mo 
Daudi  0  35  42 
8866  5  2  2 
Wil2WT  2-3  1  0 
SCRF5001  100  89  95 
SCRF5004  100  92  90 
SCRF5005  100  90  90 
Raji  100  92  100 
Sommer 8432  100  87  95 
Sommer 8402  0  53  60 
being identical had to be investigated. In order to answer this question inhibition 
of rosette formation between Raji cells and either C3b or C3d carrying sensitized 
red cells with isolated human C3 or C3b and human and mouse serum containing 
C3 was attempted. Table III shows that preincubation of Raji cells with isolated 
human  C3  or  C3b,  as  well  as  with  human  or  mouse  serum,  inhibited  rosette 
formation with EAC1423b hu but did not have any effect on rosette formation with 
EAC1423d hu and EAC1-3 mo. These results indicate that the receptor for C3-C3b 
and the receptor for C3d are different. 
Binding of Soluble C3 or C3b and RBC Bound C3b to Lymphocyte Receptors 
for  C3-C3b.  We  have  previously demonstrated  that  soluble  C3,  soluble  C3b, 
and  RBC-bound  C3b  bind  to  the  same  receptor  (14).  Therefore, receptors for 
C3-C3b on lymphoid cells can be shown by staining cell bound C3 or C3b with 
FITC anti-C3 serum or by rosette formation with EAC1423b hu. The requirements 
for  rosette  formation  and  binding  of soluble  C3  and  C3b  may  be  different, 
resulting in different sensitivities of the two methods. Since certain cell lines did 
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to bind soluble C3 or C3b. Thus, the ability of the nine human cell lines to bind 
soluble  C3  and  C3b  was  compared to their ability to form rosettes with  C3b 
carrying sensitized  red  cells,  i.e.,  EAC1423b hu  and  EACI-5  rab.  EACI-5  rab, 
although prepared with C6-deficient rabbit serum, carry C3b as demonstrated by 
positive  immune  adherence reactions with  human  group  O  erythrocytes. The 
results  summarized  in  Table  IV  indicate  that  with  most  cell  lines  (Raji, 
TABLE  III 
Effect on Rosette Formation by  Treatment of Raji Cells with 
Human C3 or C3b and Human or Mouse Serum 
Treatment*  Indicator cells  Rosettes 
% 
Raji +  C3  EAC1423b hu  0 
EAC1423d hu  90 
EAC1-3 mo  85 
Raji +  C3b  EAC1423b hu  0 
EAC1423d hu  92 
EAC1-3 mo  87 
Raji +  human serum  EAC1423b hu  0 
EAC 1423d hu  89 
EAC1-3 mo  85 
Raji +  mouse serum  EAC1423b hu  0 
EAC1423d hu  90 
EACI-3 mo  83 
* 2  ×  10  e Raji cells were incubated with 150 ttg human C3 or C3b and 100 
ttl  of fresh  human  or  mouse  serum,  washed  three  times,  and  then 
incubated with the different indicator EAC'. 
TABLE  IV 
Comparison of the Binding of Soluble C3 or C3b with the Binding 
of RBC Bound C3b to Lymphocyte Membrane C3-C3b Receptors 
Cell type 
Percentage of lymphoid cells 
forming rosettes with: 
Percentage of lymphoid cells 
binding 
Human C3 
EAC1423b hu  EAC1-5 rab  or C3b*  Rabbit C35 
Daudi  0  2  90  100 
8866  5  3  5  83 
Wil2WT  2-3  1  2-3  65 
SCRF5001  100  80  100  100 
SCRF5004  100  70  100  92 
SCRF5005  100  85  100  90 
Raji  100  100  100  100 
Sommer 8432  100  100  100  100 
Sommer 8402  0  0  0  0 
* Cells  were incubated  with  100  ttg  human C3  or  C3b  and  stained  with FITC 
rabbit antihuman C3. 
$ Cells  were  incubated  with  50  ttl  rabbit  serum  and  stained  with  FITC  goat 
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SCRF5001,  SCRF5004,  SCRF5005,  Sommer  8402)  there  was  good  correlation 
between their ability to bind soluble C3 and C3b and their ability to form rosettes 
with EAC1423b hu and EACI-5 rab. However, with certain cell lines (Daudi, 8866, 
Wil2WT) the detection of receptors for C3-C3b by immunofluorescence was more 
sensitive than by the rosette technique.  For example, Daudi  cells bound soluble 
human  C3  and  C3b  as  well as  rabbit  C3  but  were  unable to form rosettes with 
EAC1423b hu  or  EACI-5  rab;  8866  and  Wil2WT  cells  bound  soluble  C3  from 
rabbit serum but did not form rosettes with  EAC1-5  rab. 
The discrepancy between the results obtained for binding soluble C3-C3b and 
for binding  red  cell-bound  C3b to certain  cells  may be explained  by a  different 
distribution  of  receptors  on  the  cell  membrane.  In  effect,  distribution  of  the 
C3-C3b  receptors  on  Raji  and  other  cell  lines  able  to  form  rosettes  with  C3b 
carrying red  cells  different  than  the  distribution  on Daudi  cells  unable to form 
rosettes  with  C3b  carrying  red  cells  was  observed  by  immunofluorescence.  As 
shown in Fig.  1, Raji cells carrying C3 or C3b and stained with FITC antihuman 
C3 showed a uniform, fine granular staining pattern whereas Daudi cells carrying 
C3 or C3b showed  a  reticulated  distribution  of the stain on the  cell surface. 
Species  Specificity  of  the  C3-C3b  Receptor  on  Human  Lymphoblastoid 
Cells.  In  the  preceding  paragraph  it  was  shown  that  8866  and  Wil2WT  cells 
bound  rabbit  C3  but  not  human  C3  whereas  other  cell  lines  bound  C3  of both 
species,  which  indicated  differences  in  specificity  of C3-C3b  receptors.  In  the 
following  experiment,  the  species  specificity  of the  C3-C3b  receptor on  human 
lymphoblastoid  cells  was  analyzed  by using  C3  of different  species.  Cells  were 
incubated with isolated human C3 and C3b as well as human, mouse, rabbit, and 
guinea pig sera as sources of C3 of the different species. Cells were stained with 
the  corresponding  fluoresceinated  anti-C3  serum.  The  results  summarized  in 
FIG. 1.  Demonstration of different immunofluorescent staining patterns of C3 or C3b bearing 
Raji and Daudi cells when stained  with FITC anti-C3 serum.  (a} Raji cells with uniform, fine 
granular staining. (b) Daudi cells with reticulated distribution  of the stain.  × 1,234. 884  IMMUNE  COMPLEX  BINDING  TO  COMPLEMENT RECEPTORS 
Table V indicate a broad spectrum of specificities of C3-C3b receptors on some of 
the cells. Raji, Daudi, SCRF5001, SCRF5004, SCRF5005, and Sommer 8432 cells 
bound C3  of human,  mouse,  rabbit,  and  guinea pig origin,  as well as  isolated 
human  C3  and  C3b.  In  contrast,  8866  and  Wil2WT  cells  bound virtually no 
human  C3  and  C3b  but  interacted  with  mouse,  rabbit,  and  guinea  pig  C3. 
Finally, Sommer 8402  cells did not bind isolated human C3 and C3b nor C3 of 
any of the other species. Of all cell types tested with human, mouse, rabbit, and 
guinea  pig C3,  Raji  and Daudi  cells showed the strongest fluorescent staining 
which indicated that these cells had  a  large number of C3-C3b  receptors. The 
TABLE V 
Binding of Human C3 and C3b and C3 Present in Sera from 
Different  Species  to Human Lymphoblastoid  Cells 
Cell type 
Cells binding*  Cells binding  S C3 present 
human  in sera of: 
Guinea 
C3  C3b  Human  Mouse  Rabbit  pig 
%  % 
Daudi  90  85  90  100  100  85 
8866  5  5  5  80  83  90 
Wi|2WT  2  3  2  2-3  70  65  70 
SCRF5001  100  100  100  95  100  100 
SCRF5004  100  100  100  100  92  90 
SCRF5005  100  100  100  100  90  100 
Raji  100  100  100  100  100  95 
Sommer 8432  100  100  100  100  100  70 
Sommer 8402  0  0  0  0  0  0 
* Cells were  incubated  with  100 ttg human  C3  or C3b  and stained with 
FITC rabbit  antihuman C3. 
S Cells were incubated with 50 ttl of the different sera and stained with the 
corresponding FITC  anti-C3 serum. 
results  showed that  C3-C3b  receptors on the lymphoblastoid cells tested have 
different species specificities. 
Identification  of  Receptors  for IgG  Fc  and  Receptors  for  C3-C3b  and  C3d. 
Since  AHG  as  well  as  C3,  C3b,  and  C3d  all  bound  to  certain  cell  types,  we 
questioned whether receptor sites for IgG Fc were identical to either of the two 
receptors  for  complement,  i.e.,  the  receptors  for  C3-C3b  or  C3d.  That  the 
receptors for IgG Fc and the receptors for complement are different was shown by 
inhibition experiments. As shown in Table VI, preincubation of 5 ×  108 Raji cells 
with 100 ug AHG did not inhibit binding of C3 or C3b and preincubation with 100 
ttg  C3  or  C3b  did  not  inhibit  binding  of  AHG  to  the  cells.  Furthermore, 
preincubation of cells with AHG did not interfere with rosette formation with 
EAC  1423b hu and EAC1423d  ~u. 
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TABLE  VI 
Demonstration  of Distinct Receptors/or IgG Fc and C3-C3b 
on Raft Cells 
885 
1st  2nd  3rd  Fluorescence 
incubation  incubation  incubation  positive cells 
Raji +  AHG  C3 
Raji +  AHG  C3b 
Raji+ AHG  NHS 
Raji +  C3  FITC AHG 
Raji+ C3b  FITC AHG 
% 
FITC Rabbit antihuman C3  100 
FITC Rabbit antihuman C3  100 
FITC Rabbit antihuman C3  100 
Rabbit antihuman IgG  100 
Rabbit antihuman IgG  100 
Containing  Complement  to  Cells.  After describing the  receptors  for IgG Fc, 
C3-C3b, and C3d on the various human lymphoblastoid cells, we employed the 
characterized  cells  to  study  each  receptor's  contribution  to  the  binding  of 
immune complexes to these cells. Immune complexes in fresh serum may bind to 
cells via either the receptors for complement or via the receptors for IgG Fc, or 
both. Since whole serum contains C3b inactivator which can cleave C3b into C3c 
and C3d, immune complexes in whole serum may contain C3b, or C3d, or both 
C3 fragments. AHG was employed as an immune complex because it has been 
shown that AHG possesses many of the properties of antigen-antibody complexes 
(21,  22).  In  order  to  find out  which  of the  receptors  (IgG  Fc,  C3-C3b,  C3d) 
mediates binding of complexes which have interacted with serum as the source of 
complement, the following experiments were performed. Different batches of 2.5 
×  10 ~  Raji cells were incubated (37 °C, 30 rain) with 200 #g human IgG (cells with 
blocked receptors  for IgG  Fc),  washed  twice with medium, and  then  reacted 
(37°C, 45 rain) with 5 ttg of [125I]AHG in 20 #l MEM, in 20 #l heated (56°C, 30 
min)  human serum or in  20 ttl fresh human serum.  Cells which had not been 
preincubated with IgG  (cells with nonblocked receptors for IgG Fc)  were also 
reacted with 5 #g  [I~sI]AHG in 20 #l MEM, in 20 #l heated human serum or in 
20 #1 fresh human serum. As depicted in Fig. 2, there was virtually no uptake by 
cells with blocked receptors for IgG Fc of [12~I]AHG in MEM or in heated serum, 
whereas cells with nonblocked receptors for IgG Fc bound between 0.1 and 0.15 
#g of these aggregates. However, there was virutally no difference between the 
two types of cells in uptake of aggregates containing complement. The results 
indicate that AHG containing complement binds to cells only via the receptors 
for complement, since blocking of the receptors for Fc did not have any effect on 
the binding of these aggregates. It should be  noted (Fig.  2)  that the uptake of 
AHG containing complement was approximately eight times higher than that of 
AHG without complement. The fact the AHG containing complement bound to 
Raji  cells  only  via  the  receptors  for  complement  was  also  demonstrated  in 
experiments in which the receptors for complement were removed from the cells 
by trypsin treatment. We showed previously that trypsin destroys the receptors 
for C3-C3b on Raji cells (14). In the present study it was found that trypsin also 
destroys the receptors for C3d on Raji cells since trypsin-treated Raji cells were 
unable to form rosettes with EAC1423d  hu or EAC1-3 too. However, the receptors 886  IMMUNE  COMPLEX  BINDING  TO COMPLEMENT  RECEPTORS 
for IgG Fc on Raji cells were resistant to trypsin since treated cells were still able 
to bind AHG. Utilizing trypsin-treated and untreated cells we were able to assess 
the  contribution  of the  receptors for IgG Fc and  complement to the  binding of 
immune complexes to cells. As shown in Table VII, FITC AHG incubated with 
fresh  human  serum  as  the  source  of complement,  only  bound  to  nontrypsin- 
treated cells whereas FITC AHG or FITC AHG incubated with heat-inactivated 
1.4 
1.2- 
× 
~  o.r 
~  0.6- 
~. o.4- 
~  0.2 
Cells With  Non-  Cells  With 
•  Blocked Receptors  Blocked Receptors 
for IgG Fc  for  IgG F¢ 
AHC  AHG  ABC  AHG  - 
M6  R;oted M6  +  +  NHS Heated 
HS  HS 
FiG.  2.  Uptake of [~2~I]AHG by Raji cells in the presence or absence of complement. Aliquots 
of 2.5  ×  106 Raji cells with nonblocked and blocked receptors for IgG Fc were incubated with 5 
pg of [lzSI]AHG  in MEM, in fresh human serum or in heat-inactivated (56°C, 30 rain) human 
serum. The IgG Fc receptors were blocked by incubating the cells with human IgG. 
TABLE  VII 
Demonstration of the Binding of AHG Containing Complement to 
Raft Cells via the Complement Receptors 
Positive 
Cells  Treatment*  Incubation~  cells 
% 
Raji  None  FITC AHG  100 
Raji  Trypsin  FITC AHG  100 
Raji  None  FITC AHG +  heated HS  100 
Raji  Trypsin  FITC AHG + heated HS  100 
Raji  None  FITC AHG +  NHS  100 
Raji  Trypsin  FITC AHG +  NHS  3  5 
* 5  ×  106 Raji cells were incubated (37°C,  15 min) with MEM or with a 
0.01%  (wt/vol) solution of trypsin in MEM. The effect of trypsin was 
stopped by washing the cells three times with 0.1% solution of soy bean 
trypsin inhibitor in MEM. 
Trypsin and nontrypsin treated cells were incubated (37°C, 30 min) with 
FITC AHG in medium or with FITC AHG which had reacted (37°C, 30 
min) with heat-inactivated (56°C, 30 rain) or fresh NHS. A.  N.  THEOFILOPOULOS,  F.  J.  DIXON,  AND V.  A.  BOKISCH  887 
(56°C, 30 min) human serum bound to both nontrypsin- and trypsin-treated Raji 
cells. The results again indicate that binding of AHG which had interacted with 
complement is solely mediated by the receptors for complement. 
Contribution  of  the  Receptors  for  C3-C3b  and  C3d  to  the  Binding  of 
AHG-Containing  Complement  to  Cells.  In  the preceding section we demon- 
strated  that  AHG  in  fresh  serum  binds  to  cells  only  via  the  receptors  for 
complement. However, since Raji cells have both receptors for C3-C3b and C3d 
and immune complexes incubated with whole serum may contain C3b,  C3d, or 
both C3 fragments, experiments were carried out in order to define which of the 
two receptors fbr complement is operative in the binding of immune complexes to 
the cells. In these experiments 12~I-labeled AHG and F1TC AHG were employed. 
Different batches of 2.5  ×  10 ~ Raji cells were incubated with 100 ttg C3,  100 ttg 
C3b,  50 ttl NHS,  or 50 ttl MEM. The washed cells were then reacted with 5 #g 
[L25I]AHG containing complement and the uptake of [125I]AHG by the different 
batches of cells was measured. Cells preincubated with C3,  C3b, or NHS bound 
only  approximately  50%  of the  amount  of  [12~I]AHG taken  up  by  the  cells 
incubated  in  MEM  (Fig.  3).  Similar  results  were  obtained  when  FITC 
AHG-containing complement was used; these aggregates also bound to cells with 
blocked  receptors  for C3-C3b.  Thus,  when  cells were  incubated with  isolated 
human C3,  C3b, or human serum and then reacted with FITC AHG which had 
previously interacted with whole human serum, fluorescence staining of the cells 
was observed.  The results showed that AHG-containing complement binds to 
cells via both receptors for C3-C3b and C3d. 
Release of AHG-Containing Complement from the Cell Surface.  It has been 
previously  shown  by  Miller  et  al.  (23) that  immune  complexes  containing 
complement bound to mouse lymphocytes can be released from the cell surface 
o~ 
× 
1.4 
1.2 
O'6  I 
0.2- 
Raji  Raji  Raji  Raji 
MEM  N  $  C3  C3b 
Fm.o3.  Uptake of  [--I]AHG by Raji cells in the presence of complement before and after 
blockage of receptors for C3-C3b. Aliquots of 2.5  ×  10  ~ Raji cells were incubated with MEM, 
NHS, C3, or C3b and then reacted with 5 ttg  [12~I]AHG in the presence of complement• 888  IMMUNE COMPLEX  BINDING  TO COMPLEMENT  RECEPTORS 
by  incubating the  cells  in  fresh  whole  human  or  mouse  serum,  but  not  by 
incubating  them  with  isolated  human  C3  or  C3b.  The  mechanism  of  this 
phenomenon has not been fully elucidated. Therefore, we decided to investigate 
the release phenomenon by using Raji cells. Different batches of 2.5  ×  l0 s Raji 
cells coated with a  certain amount of  [12SI]AHG containing complement were 
prepared  by  incubating  each  batch  of  cells  with  5  ttg  of these  aggregates. 
Subsequently, AHG-coated cells were incubated (37°C,  45  min)  with different 
amounts of human serum, purified human C3 or C3b. Control AHG-coated cells 
were incubated with medium containing 0.1% HSA. After incubation, supernates 
were  collected  and  radioactivity present  in  supernates  and  on  the  cells  was 
assessed. As depicted in Fig. 4, approximately 44% of the [12~I]AHG was released 
6°  T 
50 
~ 40- 
30- 
20- 
10- 
~NHS 
jJ~ ~  ~  c3b 
oMEM 
b  ~  100  6.25 12.5  2i5  5tO 
ul of Solution Added to Cells 
FI6.  4.  Demonstration of release of Raji cell-bound ['25I]AHG by NHS, C3, or C3b. Aliquots 
of 2.5  x  10  e Raji cells were coated with  [~2~I]AHG which had interacted with fresh human 
serum. Subsequently cells were incubated with various amounts of NHS, C3, C3b, or MEM 
containing 0.1%  HSA. The final vol in each point was adjusted to 200,1 with MEM.  NHS 
contained 1.5 mg C3/ml. Isolated human C3 and C3b were at concentrations of 1.5 mg/ml. 
from the cells by 100 ttl of whole fresh NHS containing 150 tLg C3. As is shown also 
in Fig. 4, when 100 t~l of a solution containing 150 pg human C3 or C3b was added 
to  [125I]AHG-coated  cells,  approximately 41%  and 34% of the bound AHG was 
released,  respectively.  The  percent  of  released  radioactivity  was  decreased 
proportionately with the amount of serum, C3 or C3b used. The results indicate 
that  NHS  and  purified human  C3  or  C3b  can  release some AHG  containing 
complement bound to Raji cells. 
Discussion 
In the present work, we studied MBIg and receptors for IgG Fc and complement 
of nine different human lymphoblastoid cell lines having B-type cell characteris- 
tics.  Some  of  the  cell  lines  studied  expressed  all  of  the  described  B-type 
lymphocyte markers  (MBIg,  receptors  for IgG Fc,  receptors  for complement). 
However, other cell lines showed only some of these markers. For example: we 
found cell lines without MBIg but with receptors for IgG Fc and complement, cell 
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and  cell  lines  without MBIg and  receptors  for IgG Fc  but  with receptors  for 
complement. The data suggest that cell lines lacking certain B-cell markers may 
be derived from B cells which did not express all the surface markers, such as B 
cells at different stages of maturation or B cells belonging to different subclasses. 
On  the other hand,  cultured cells may have lost surface receptors which were 
present  on  the  cells from which they were  derived.  For example,  it has  been 
shown that three subclasses of B-type lymphocytes are present in the blood of 
patients with chronic lymphocytic leukemia; cells having only MBIg, cells having 
only receptors for C3 and cells having both MBIg and receptors for C3 (24).  In 
addition,  in  patients  with  X-linked  agammaglobulinemia,  lymphocytes 
without MBIg but with receptors for C3 have been described (25).  Furthermore, 
loss of MBIg has been reported to occur in cultured cells (26). 
Dickler et al. (27) have shown with human peripheral lymphocytes that there is 
a correlation between presence of MBIg and receptors for IgG Fc. The cell lines 
studied here did not show such an absolute correlation. For example, as noted 
above, cell lines without MBIg but with receptors for IgG Fc (Raji, Sommer 8432) 
and cell lines with MBIg but without receptors for IgG Fc (Wil2WT, 8866) were 
encountered.  Absence  of receptors  for IgG Fc  on Wil2WT and 8866 cells was 
shown not only by the direct fluorescent method but also by the more sensitive 
indirect method, which, according to Dickler et al. (27) and our own experience, 
can detect binding to cells of small size aggregates or 7S IgG. 
Two types of receptors for complement were found to be present on the cell 
lines  tested,  one  for  C3  and  C3b  and one  for C3d.  Using sensitized red  cells 
carrying C3b or C3d, it was found that some cell lines have both receptors for C3b 
and  C3d,  while  others  have  only receptors  for  C3d,  and  others  have neither 
receptor.  By  using  the  rosette  test,  it  was  shown  that  all  cell  lines  having 
receptors for C3b also had receptors for C3d. Similar results with other cell lines 
have been reported by Ross et al. (3)  and Dierich et al. (28). 
In addition to the rosette test, the more sensitive fluorescent technique was 
used for detecting C3-C3b receptors on cells. By employing this technique it was 
found that cell lines unable to form rosettes with EAC1423b hu and EACI-5 rab 
bound  soluble  C3  and  C3b.  Sommer 8402  is  the only cell  line of those tested 
which did not reveal  a  C3-C3b  receptor by either method. Since this cell line 
formed rosettes with EAC1423d hu and EAC1-3 mo, we concluded that it has only 
the C3d receptor. 
The  different sensitivities of the  immunofluorescence and the rosette tech- 
niques in demonstrating C3-C3b receptors may be due to the fact that EAC' is a 
large particle and in order to attach to cells it may require a special arrangement 
as  well as a  large number of C3-C3b receptors on the surface of the lymphoid 
cells.  In fact,  a  difference in the distribution of the receptors  for C3-C3b  was 
observed  by  immunofluorescence  between  cells  able  to  form  rosettes  with 
EAC1423b h~  and  EAC1-5  rab,  and  cells  (Daudi)  which were  unable  to  form 
rosettes with EAC1423b h~ and EACI-5 rab. That the rosette technique does not 
always detect  C3-C3b  receptors  on  the  cell  surface  is  also  supported  by the 
demonstration  of Dierich  (personal  communication),  who  found  C3  receptor 
activity in solubilized cell extracts from lymphoid cell types which do not form 
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mucoids  derived  from  bovine  erythrocytes inhibited  the  interaction  of EAC- 
1423b hu  with  human  erythrocytes  which  carry  C3b  receptors,  whereas  no 
interaction was observed with bovine red cells by themselves and EAC1423b hu. 
In several reports on the classification of peripheral human lymphocytes as T 
and B  cells,  it has been stated that the percentage of' B cells having MBIg was 
higher than that of B cells having C3b receptors (24, 30, 31). In those studies, C3b 
receptors  were  demonstrated by the  rosette  technique.  Since the fluorescence 
method is more sensitive in detecting C3b receptors than the rosette technique, it 
may  reveal  a  percentage  of  C3b  receptor-bearing  cells  similar  to  that  of 
Ig-bearing  cells.  We  had  already  {ound  that  approximately  20%  of  human 
peripheral  lymphocytes  bound  soluble  C3b  (14). 
We have previously shown that the receptors for C3 and C3b are identical (14). 
In the present study we demonstrated that the receptors for C3-C3b are distinct 
from the receptors  fbr C3d.  Other experimental data also support the concept 
that  C3-C3b  and C3d  receptors  are  independent. Ross et al.  have shown that 
human red cells have only C3b receptors (3). The same authors used antisera to 
C3b and C3d receptors to show that the two receptors are distinct on the surface 
of human peripheral lymphocytes and cells of lymphoid cell lines (3). 
A  broad  spectrum of species  specificity of C3-C3b  receptors  on the  human 
lymphoblastoid cell  lines studied was shown by using C3 of different species. 
Whereas the majority of cell lines bound human C3 and C3b as well as mouse, 
rabbit, and guinea pig C3,  some cell lines did not bind human C3 and C3b but 
were able to bind mouse, rabbit and guinea pig C3. The reason that some cell 
lines did not bind human C3  and C3b  but bound C3 from other species is not 
understood. It may be that the specificity of C3  receptors of' human lymphoid 
cells is altered in culture. 
The receptors for IgG Fc and the receptors for C3-C3b  and C3d are distinct 
since inhibition experiments demonstrated that Raji cells with blocked receptors 
for  IgG  Fc  were  able  to  bind  soluble  C3  and  C3b  and  to  form  rosettes  with 
sensitized red cells carrying C3b or C3d. The possibility that the receptors fbr IgG 
Fc, C3-C3b, and C3d are a class of Ig is excluded by the fact that Raji cells do not 
carry MBIg. 
The contribution of each of' the three receptors to the binding of soluble im- 
mune complexes containing complement to cell surfhces was assessed by using 
Raji cells which have IgG Fc,  C3-C3b,  and C3d receptors. It was demonstrated 
that the receptors  for complement are far more important in binding immune 
complexes containing complement than receptors for Fc. In fact, it was shown 
that the binding of' AHG containing complement was primarily mediated via the 
receptors  for complement,  since  the  amount of AHG containing complement 
bound to cells with or without blocked receptors fbr Fc was virtually the same. In 
contrast,  the  binding  of  AHG  without  complement  was  almost  completely 
inhibited when cells with blocked receptors for Fc were used. The importance of 
complement receptors  in  the  binding of complexes containing complement to 
cells was further demonstrated by using Raji cells with and without receptors for 
complement. Receptors for complement, but not IgG Fc, were removed from the 
cells by mild trypsin treatment. When these cells were used,  it was found that 
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receptors,  whereas  AHG  containing complement  bound  only  to  complement 
receptor carrying Raji cells. Our findings indicate that the increased binding to 
cells  of AHG  containing complement,  as  compared  to  that  of AHG  without 
complement,  is  not  due  to  additive  binding  via  both  Fc  and  complement 
receptors but is due to binding via complement receptors only. These results are 
in  agreement with  the  studies of Eden,  Bianco,  and  Nussenzweig,  who  have 
postulated that the complement mediated binding affects and impedes the Fc 
mediated binding of immune complexes to lymphocytes (32). According to these 
authors, complement bound to the antibody within the complexes may sterically 
hinder or directly bind to the sites on the Ig molecules which have affinity for the 
lymphocyte membrane.  Although  soluble  aggregates  containing complement 
bind to cells primarily via complement receptors, it should be noted that in other 
systems it has been shown that receptors  for IgG Fc play a  significant role in 
other cell functions such as phagocytosis of EAC' (33,  34). 
In  the  course of complement activation,  C3b  binds  to  immune complexes. 
Complex-bound C3b is thereafter cleaved by the serum enzyme C3b inactivator 
into C3c  and C3d,  with the d portion remaining on the immune complex (17). 
Therefore, immune complexes in whole serum may contain C3b,  C3d, or both. 
Experiments presented here indicated that both receptors for C3-C3b  and C3d 
are operative in binding of immune complexes coated with complement to cells. 
These experiments also suggested that Raji cells have approximately the same 
number of receptors  for C3;C3b  and  C3d  on  their  surface since  it  was  found 
that 50% of aggregates that bound to cells with nonblocked receptors for C3-C3b 
could still bind to cells with blocked receptors for C3-C3b. 
Miller,  Saluk, and Nussenzweig showed that immune complexes containing 
complement bound to murine B lymphocytes could be released from the cells by 
addition of NHS  but not  by addition of isolated human C3 or C3b  (23).  The 
authors postulated that release is due to activation of the alternate pathway of 
the complement system by complex-coated cells, which results in the generation 
of products which modify or cover the C3 binding sites on the complexes which 
are then released. In our experiments, NHS as well as isolated soluble human C3 
and C3b could release a substantial percentage of' immune complexes bound to 
Raji cells via receptors fbr complement. Since in our study not only whole serum 
but also isolated C3 or C3b were able to release immune complexes bound to Raji 
cells, we postulated that release of complexes from Raji cells by human serum is 
due to the presence in serum of C3 or C3b. C3b could be generated by activation 
of complement by immune complexes at the site of binding. We have previously 
shown that C3 or C3b competes with the red cell-bound C3b  (EAC  1423b) for 
receptors for C3-C3b on Raji cells because addition of C3 or C3b to Raji-EAC 
1423b hu rosettes resulted in dissociation of rosettes (14).  Additional evidence of 
competition between free C3 and C3b and complexes containing complement for 
the receptors for complement has been obtained by other experiments in which 
uptake of AHG by Raji cells was greatly diminished when an excess of human 
serum was present. 3  NHS as well as C3 and C3b were unable to release more than 
approximately 50%  of cell-bound  complement-coated aggregates,  which  may 
3  Theofilopoulos, A. N., and F. J. Dixon. Manuscript in preparation. 892  IMMUNE  COMPLEX  BINDING  TO  COMPLEMENT  RECEPTORS 
again indicate that part of immune complexes are bound to cells via the receptors 
for C3d. 
Summary 
In the present work we studied the expression of membrane-bound Ig (MBIg) as 
well as receptors for IgG Fc and complement on nine human lymphoblastoid cell 
lines. When MBIg and receptors for IgG Fc were compared, four categories of cell 
lines could be distinguished:  (a) cell lines having both MBIg and receptors for 
IgG Fc, (b) cell lines having MBIg but lacking receptors for IgG Fc, (c) cell lines 
lacking MBIg but having receptors for IgG Fc,  and  (d) cell lines lacking both 
MBIg and receptors for IgG Fc. Two types of receptors for complement could be 
detected  on  the  cell  lines  studied,  one  for  C3-C3b  and  one  for  C3d.  When 
sensitized  red  cells  carrying  C3b  or  C3d  were  used  for  rosette  tests,  three 
categories of cell lines could be distinguished:  (a) cell lines having receptors for 
C3b and C3d, (b) cell lines having receptors only fbr C3d and (c) cell lines lacking 
both receptors. However, when a more sensitive immunofluorescent method was 
used instead of the rosette technique, it was found that cell lines unable to form 
rosettes with EAC1423b hu were able to bind soluble C3 or C3b which indicated 
the presence of these receptors on the cell surface. Inhibition experiments showed 
that receptors for C3-C3b and receptors for C3d are distinct and that receptors for 
C3-C3b and C3d are different from receptors for IgG Fc. 
A cell line (Raji) without MBIg but with receptors for IgG Fc, C3-C3b, and C3d 
was  selected  for  use  in  studying  the  binding  mechanism  of soluble  immune 
complexes to cell surface membrane. Aggregated human  gamma  globulin was 
used in place of immune complexes. Immune complexes containing complement 
bind to Raji cells only via receptors for complement, namely receptors for C3-C3b 
and C3d. Binding of immune complexes containing complement to cells is much 
greater than that of complexes without complement. Immune complexes bound 
to  cells  via  receptors  for  complement  can  be  partially released from  the  cell 
surface by addition of normal human serum as well as isolated human C3 or C3b. 
We postulate that such release is due to competition of immune complex bound 
C3b and free C3 or C3b for the receptors on Raji cells. 
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